LITTLE FALLS, N.J., Feb. 16, 2017 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE:CMD), a leading global company dedicated to delivering innovative infection prevention products, services and solutions, announced today that it entered into a definitive agreement to purchase its endoscopy business assets from Australian distributor, CR Kennedy & Company Pty Ltd. The endoscopy business assets consist of Cantel's Medivators®-branded automated endoscope reprocessors, chemistries, procedure room products and other consumables as well as a full sales and service organization.
Jorgen B. Hansen, President and CEO of Cantel Medical said, "This acquisition is in line with Cantel's strategy to expand its products and services into key markets to provide global solutions that meet local needs. It also accelerates our ability to offer customers in Australia an expanded Medivators®-branded product portfolio while maintaining the high-quality service and support that our customers expect."
"The expansion of our commercial platform and the addition of a direct sales and service organization for our Endoscopy business provides Cantel with near- and long-term growth opportunities. It also broadens our leadership and strengthens our share in the infection prevention market in Australia," stated David Rosen, President, Continental Europe, Middle East and Asia-Pacific. "We would like to thank CR Kennedy for the many years of outstanding support of the Medivators® business in Australia and for their partnership and role in helping us achieve this milestone."
Subject to customary closing conditions, Cantel expects the transaction to close on or around April 1, 2017.
About Cantel MedicalCantel Medical is a leading global company dedicated to delivering innovative infection prevention products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products. Additionally, we provide technical service for our products. For further information, visit the Cantel website at www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
Advertisement
Jorgen B. Hansen, President and CEO of Cantel Medical said, "This acquisition is in line with Cantel's strategy to expand its products and services into key markets to provide global solutions that meet local needs. It also accelerates our ability to offer customers in Australia an expanded Medivators®-branded product portfolio while maintaining the high-quality service and support that our customers expect."
Advertisement
"The expansion of our commercial platform and the addition of a direct sales and service organization for our Endoscopy business provides Cantel with near- and long-term growth opportunities. It also broadens our leadership and strengthens our share in the infection prevention market in Australia," stated David Rosen, President, Continental Europe, Middle East and Asia-Pacific. "We would like to thank CR Kennedy for the many years of outstanding support of the Medivators® business in Australia and for their partnership and role in helping us achieve this milestone."
Subject to customary closing conditions, Cantel expects the transaction to close on or around April 1, 2017.
About Cantel MedicalCantel Medical is a leading global company dedicated to delivering innovative infection prevention products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products. Additionally, we provide technical service for our products. For further information, visit the Cantel website at www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cantel-medical-to-expand-direct-sales-operations-in-australia-300408905.html
SOURCE Cantel Medical Corp.
